MIF and neoplasm: In contrast, tumor cells showed a marked reduction in both the number and strength of interactions after anti–PD-1/anti-MIF combination therapy, while selectively strengthening connections with CD8+ T cells (Figure 9A and Supplemental Figure 8A).